DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.

BACKGROUND: Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later...

全面介紹

書目詳細資料
Main Authors:	Jones, R, Sheehan, B, Phillips, P, Juszczak, E, Adams, J, Baldwin, A, Ballard, C, Banerjee, S, Barber, B, Bentham, P, Brown, R, Burns, A, Dening, T, Findlay, D, Gray, R, Griffin, M, Holmes, C, Hughes, A, Jacoby, R, Johnson, T, Knapp, M, Lindesay, J, McKeith, I, McShane, R, Macharouthu, A, O'Brien, J, Onions, C, Passmore, P, Raftery, J, Ritchie, C, Howard, R
格式:	Journal article
語言:	English
出版:	BioMed Central 2009

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.

相似書籍